HWA
TEVA icon

HCR Wealth Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

HCR Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,971
Closed -$216K – 161
2016
Q4 		$216K Buy
+5,971
New +$238K 0.11% 132

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HCR Wealth Advisors's TEVA Position: Q1 2017 in Review

HCR Wealth Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2017, closing a stake of 5,971 shares — an estimated $216K sold.

HCR Wealth Advisors first reported a position in TEVA in Q4 2016 and held it in 1 quarter. The position peaked at $216K in Q4 2016. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • HCR Wealth Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2017 after selling out during the quarter.
  • HCR Wealth Advisors sold 5,971 Teva Pharmaceutical Industries Limited shares in Q1 2017, an estimated $216K.
  • HCR Wealth Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2016 and held it in 1 quarter.
  • HCR Wealth Advisors's Teva Pharmaceutical Industries Limited position peaked at $216K in Q4 2016.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2017.

Based on HCR Wealth Advisors's 13F filing for Q1 2017, filed 11 May 2017.